Abstract:Significance Identification of cancer cells in the pleural effusions of lung cancer patients is an important clinical diagnosis to verify the malignant pleural involvement. Elevated glucose uptake is a hallmark of cancer cells and has been used in positron-emission tomography to detect malignant tumors in vivo. We hypothesize that cells with enhanced glucose uptake and without expression of leukocyte markers in pleural effusion or peripheral blood samples are highly likely to be malignant cells that can be confirmed via single-cell sequencing. To this end, a high-throughput metabolic-based assay is developed for rapid detection of rare metabolically active tumor cells in pleural effusion, enabling sensitive diagnosis of malignant pleural effusion in the clinic that is associated with metastatic malignancies. Malignant pleural effusion (MPE), the presence of malignant cells in pleural fluid, is often the first sign of many cancers and occurs in patients with metastatic malignancies. Accurate detection of tumor cells in pleural fluid is crucial because the presence of MPE denotes an advanced stage of disease and directs a switch in clinical managements. Cytology, as a traditional diagnostic tool, has limited sensitivity especially when tumor cells are not abundant, and may be confounded by reactive mesothelial cells in the pleural fluid. We describe a highly sensitive approach for rapid detection of metabolically active tumor cells in MPE via exploiting the altered glucose metabolism of tumor cells relative to benign cells. Metabolically active tumor cells with high glucose uptake, as evaluated by a fluorescent glucose analog (2-NBDG), are identified by high-throughput fluorescence screening within a chip containing 200,000 addressable microwells and collected for malignancy confirmation via single-cell sequencing. We demonstrate the utility of this approach through analyzing MPE from a cohort of lung cancer patients. Most candidate tumor cells identified are confirmed to harbor the same driver oncogenes as their primary lesions. In some patients, emergence of secondary mutations that mediate acquired resistance to ongoing targeted therapies is also detected before resistance is manifested in the clinical imaging. The detection scheme can be extended to analyze peripheral blood samples. Our approach may serve as a valuable complement to cytology in MPE diagnosis, helping identify the driver oncogenes and resistance-leading mutations for targeted therapies.

Can We Improve the Cytologic Examination of Malignant Pleural Effusions Using Molecular Analysis?

Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid

A Detection Panel of Novel Methylated DNA Markers for Malignant Pleural Effusion

Combined Methylation of SHOX2 and RASSF1A Genes in Diagnosing Malignant Pleural Effusion

DNA Methylation Analysis of the SHOX2 and RASSF1A Panel Using Cell-Free DNA in the Diagnosis of Malignant Pleural Effusion

Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas

Application value of combined detection of exfoliative cytology,DNA heteroploid analysis and serum tumor marker in malignant pleural/ascitic fluid

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

Highly sensitive noninvasive early lung cancer detection using DNA methylation topology in sputum-derived epithelial cells

[A Method for Isolating Tumor Cells from Large Volume of Malignant Pleural  Effusion and Its Efficacy Evaluation].

The Diagnostic Value of FCM DNA Content for Benign and Malignant Pleural Effusion

Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum

Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review

Molecular Profiling of Lung Adenocarcinoma Using Pleural Effusion Specimens.

Pleural fluid analysis of lung cancer vs benign inflammatory disease patients

Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients

Metabonomic Classification and Detection of Small Molecule Biomarkers of Malignant Pleural Effusions

High-throughput Screening of Rare Metabolically Active Tumor Cells in Pleural Effusion and Peripheral Blood of Lung Cancer Patients